-
EP2651445
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2651445
| EP2651445 - PHARMACEUTICAL COMPOSITION CONSISTING OF RNA HAVING ALKALI METAL AS COUNTER ION AND FORMULATED WITH DICATIONS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 02.10.2020 Database last updated on 06.11.2024 | |
| Former | Examination is in progress Status updated on 11.12.2019 | ||
| Former | Grant of patent is intended Status updated on 19.09.2019 | ||
| Former | Examination is in progress Status updated on 27.12.2016 | Most recent event Tooltip | 02.10.2020 | Application deemed to be withdrawn | published on 04.11.2020 [2020/45] | Applicant(s) | For all designated states SPRNA GmbH Kanzleistrasse 23 8004 Zürich / CH | [2013/43] | Inventor(s) | 01 /
PASCOLO, Steve Kanzleistrasse 231 8004 Zürich / CH | [2013/43] | Representative(s) | Habermann, Hruschka & Schnabel Patentanwälte Montgelasstraße 2 81679 München / DE | [2013/43] | Application number, filing date | 11794809.1 | 16.12.2011 | WO2011EP73151 | Priority number, date | EP20100195493 | 16.12.2010 Original published format: EP 10195493 | [2013/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2012103985 | Date: | 09.08.2012 | Language: | EN | [2012/32] | Type: | A2 Application without search report | No.: | EP2651445 | Date: | 23.10.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.08.2012 takes the place of the publication of the European patent application. | [2013/43] | Search report(s) | International search report - published on: | EP | 27.09.2012 | Classification | IPC: | A61K47/00, C12N15/88, A61K9/00 | [2013/43] | CPC: |
A61K9/0019 (EP,US);
C12N15/117 (EP,US);
A61K47/02 (EP,US);
C12N15/11 (US);
C12N15/111 (EP,US);
C12N15/113 (EP,US);
C12N15/88 (EP,US);
C12N2310/11 (EP,US);
C12N2310/14 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/43] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS RNA MIT ALKALIMETALL ALS GEGENION UND FORMULIERT MIT DIKATIONEN | [2013/43] | English: | PHARMACEUTICAL COMPOSITION CONSISTING OF RNA HAVING ALKALI METAL AS COUNTER ION AND FORMULATED WITH DICATIONS | [2013/43] | French: | COMPOSITION PHARMACEUTIQUE À BASE D'ARN QUI COMPREND UN MÉTAL ALCALIN EN TANT QUE CONTRE-ION ET FORMULÉ AVEC DES DICATIONS | [2013/43] | Entry into regional phase | 15.07.2013 | National basic fee paid | 15.07.2013 | Designation fee(s) paid | 15.07.2013 | Examination fee paid | Examination procedure | deleted | Communication of intention to grant the patent | 15.07.2013 | Amendment by applicant (claims and/or description) | 15.07.2013 | Examination requested [2013/43] | 24.10.2014 | Despatch of a communication from the examining division (Time limit: M06) | 24.04.2015 | Reply to a communication from the examining division | 16.12.2016 | Despatch of a communication from the examining division (Time limit: M06) | 26.06.2017 | Reply to a communication from the examining division | 31.10.2017 | Despatch of a communication from the examining division (Time limit: M06) | 25.04.2018 | Reply to a communication from the examining division | 20.09.2019 | Communication of intention to grant the patent | 01.10.2019 | Observations by third parties | 11.12.2019 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 16.12.2019 | Despatch of a communication from the examining division (Time limit: M04) | 03.06.2020 | Application deemed to be withdrawn, date of legal effect [2020/45] | 29.06.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/45] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.10.2014 | Fees paid | Renewal fee | 17.10.2013 | Renewal fee patent year 03 | 08.10.2014 | Renewal fee patent year 04 | 07.10.2015 | Renewal fee patent year 05 | 21.11.2016 | Renewal fee patent year 06 | 06.11.2017 | Renewal fee patent year 07 | 17.12.2018 | Renewal fee patent year 08 | 14.10.2019 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]EP1083232 (JUNG GUENTHER PROF DR [DE], et al) [Y] 18-23 * paragraph [0049] *; | [XYI]US2008267873 (HOERR INGMAR [DE], et al) [X] 1-15,17 * paragraph [0033] - paragraph [0080] * * page 2 - page 8; examples 1-2 * [Y] 18-23 [I] 16; | [A] - PROBST J. ET AL., "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", GENE THERAPY, (20070503), vol. 14, pages 1175 - 1180, XP002679377 [A] 1-23 * the whole document * DOI: http://dx.doi.org/10.1038/SJ.GT.3302964 | Examination | WO2006008154 | by applicant | - WOLFF JA; MALONE RW; WILLIAMS P; CHONG W; ACSADI G; JANI A ET AL., "Direct gene transfer into mouse muscle in vivo", SCIENCE, (19900323), vol. 247, pages 1465 - 8 | - HOERR I; OBST R; RAMMENSEE HG; JUNG G., "In vivo application ofRNA leads to induction of specific cytotoxic T lymphocytes and antibodies", EUR J IMMUNOL, (200001), vol. 30, no. 1, doi:doi:10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.3.CO;2-R, pages 1 - 7, XP002243972 DOI: http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.3.CO;2-R | - DIEBOLD SS; KAISHO T; HEMMI H; AKIRA S; REIS E SOUSA C., "Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA", SCIENCE, (20040305), vol. 303, no. 5663, doi:doi:10.1126/science.1093616, pages 1529 - 31, XP002675306 DOI: http://dx.doi.org/10.1126/science.1093616 | - HEIL F; HEMMI H; HOCHREIN H; AMPENBERGER F; KIRSCHNING C; AKIRA S ET AL., "Species- specific recognition of single-stranded RNA via toll-like receptor 7 and 8", SCIENCE, (20040305), vol. 303, no. 5663, pages 1526 - 9 | - OZPOLAT B; SOOD AK; LOPEZ-BERESTEIN G., "Nanomedicine based approaches for the delivery of siRNA in cancer", J INTERN MED, vol. 267, no. 1, doi:doi:10.1111/j.1365-2796.2009.02191.x, pages 44 - 53, XP055242950 DOI: http://dx.doi.org/10.1111/j.1365-2796.2009.02191.x | - JARROSSAY D; NAPOLITANI G; COLONNA M; SALLUSTO F; LANZAVECCHIA A., "Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells", EUR J IMMUNOL, (200111), vol. 31, no. 11, pages 3388 - 93, XP055027927 | - PANTER G; KUZNIK A; JERALA R., "Therapeutic applications of nucleic acids as ligands for Toll-like receptors", CURR OPIN MOL THER, (200904), vol. 11, no. 2, pages 133 - 45 | - SCHEEL B; BRAEDEL S; PROBST J; CARRALOT JP; WAGNER H; SCHILD H ET AL., "Immunostimulating capacities of stabilized RNA molecules", EUR J IMMUNOL, (200402), vol. 34, no. 2, doi:doi:10.1002/eji.200324198, pages 537 - 47, XP002422103 DOI: http://dx.doi.org/10.1002/eji.200324198 | - BOURQUIN C; SCHMIDT L; HORNUNG V; WURZENBERGER C; ANZ D; SANDHOLZER N ET AL., "Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response", BLOOD, (20070401), vol. 109, no. 7, pages 2953 - 60 | - DIEBOLD SS; MASSACRIER C; AKIRA S; PATUREL C; MOREL Y; REIS; SOUSA C., "Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides", EUR J IMMUNOL, (200612), vol. 36, no. 12, doi:doi:10.1002/eji.200636617, pages 3256 - 67, XP008101287 DOI: http://dx.doi.org/10.1002/eji.200636617 | - PASCOLO S., "Vaccination with messenger RNA", METHODS MOL MED, (2006), vol. 127, pages 23 - 40, XP009117840 | - PROBST J; WEIDE B; SCHEEL B; PICHLER BJ; HOERR I; RAMMENSEE HG ET AL., "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", GENE THER, (200708), vol. 14, no. 15, doi:doi:10.1038/SJ.GT.3302964, pages 1175 - 80, XP002679377 DOI: http://dx.doi.org/10.1038/SJ.GT.3302964 | - JING N; DE CLERCQ E; RANDO RF; PALLANSCH L; LACKMAN-SMITH C; LEE S ET AL., "Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design", J BIOL CHEM, (20000204), vol. 275, no. 5, doi:doi:10.1074/jbc.275.5.3421, pages 3421 - 30, XP002952224 DOI: http://dx.doi.org/10.1074/jbc.275.5.3421 | - XU Y; ISHIZUKA T; KIMURA T; KOMIYAMA M., "A U-tetrad stabilizes human telomeric RNA G-quadruplex structure", J AM CHEM SOC, vol. 132, no. 21, pages 7231 - 3 | - PAN B; SHI K; SUNDARALINGAM M., "Synthesis, Purification and Crystallization of Guanine-rich RNA Oligonucleotides.", BIOL PROCED ONLINE, (2004), vol. 6, pages 257 - 62 | - KERKMANN M; COSTA LT; RICHTER C; ROTHENFUSSER S; BATTIANY J; HORNUNG V ET AL., "Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells", J BIOL CHEM, (20050304), vol. 280, no. 9, doi:doi:10.1074/jbc.M410868200, pages 8086 - 93, XP002454062 DOI: http://dx.doi.org/10.1074/jbc.M410868200 | - PASQUALI S; MOCELLIN S., "The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma", CURR MED CHEM, vol. 17, no. 29, pages 3327 - 36 | - YU Y; WU H; TANG Z; ZANG G., "CTLA4 silencing with siRNA promotes deviation of Thl/Th2 in chronic hepatitis B patients", CELL MOL IMMUNOL, (200904), vol. 6, no. 2, pages 123 - 7 | other | WO2006008154 | EP2651445 |